1. Home
  2. SABS vs PMEC Comparison

SABS vs PMEC Comparison

Compare SABS & PMEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SABS
  • PMEC
  • Stock Information
  • Founded
  • SABS 2014
  • PMEC 1984
  • Country
  • SABS United States
  • PMEC Singapore
  • Employees
  • SABS N/A
  • PMEC N/A
  • Industry
  • SABS Biotechnology: Pharmaceutical Preparations
  • PMEC
  • Sector
  • SABS Health Care
  • PMEC
  • Exchange
  • SABS Nasdaq
  • PMEC Nasdaq
  • Market Cap
  • SABS 32.1M
  • PMEC 28.6M
  • IPO Year
  • SABS N/A
  • PMEC 2023
  • Fundamental
  • Price
  • SABS $3.53
  • PMEC $0.74
  • Analyst Decision
  • SABS Strong Buy
  • PMEC
  • Analyst Count
  • SABS 5
  • PMEC 0
  • Target Price
  • SABS $12.40
  • PMEC N/A
  • AVG Volume (30 Days)
  • SABS 69.6K
  • PMEC 1.4M
  • Earning Date
  • SABS 11-06-2024
  • PMEC 12-31-2024
  • Dividend Yield
  • SABS N/A
  • PMEC N/A
  • EPS Growth
  • SABS N/A
  • PMEC N/A
  • EPS
  • SABS N/A
  • PMEC N/A
  • Revenue
  • SABS $1,512,723.00
  • PMEC $72,524,000.00
  • Revenue This Year
  • SABS N/A
  • PMEC N/A
  • Revenue Next Year
  • SABS N/A
  • PMEC N/A
  • P/E Ratio
  • SABS N/A
  • PMEC N/A
  • Revenue Growth
  • SABS N/A
  • PMEC 5.07
  • 52 Week Low
  • SABS $2.16
  • PMEC $0.49
  • 52 Week High
  • SABS $6.30
  • PMEC $4.15
  • Technical
  • Relative Strength Index (RSI)
  • SABS 46.39
  • PMEC 51.64
  • Support Level
  • SABS $3.50
  • PMEC $0.56
  • Resistance Level
  • SABS $4.35
  • PMEC $1.13
  • Average True Range (ATR)
  • SABS 0.41
  • PMEC 0.13
  • MACD
  • SABS -0.07
  • PMEC 0.00
  • Stochastic Oscillator
  • SABS 19.22
  • PMEC 34.36

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

About PMEC Primech Holdings Ltd.

Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.

Share on Social Networks: